These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15839012)

  • 1. A risk we have to swallow: can we ever be sure that medicines are safe before they hit the market?
    Matthews R
    New Sci; 2005 Mar 5-11; 185(2489):23. PubMed ID: 15839012
    [No Abstract]   [Full Text] [Related]  

  • 2. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [We must learn how to be better to evaluate drug benefits and risks].
    Dahl E
    Lakartidningen; 2005 Jun 27-Jul 10; 102(26-27):2003-4. PubMed ID: 16044759
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety assessment of new products developed by the pharmaceutical industry].
    Claude JR
    Ann Pharm Fr; 2001 Sep; 59(5):324-30. PubMed ID: 11787426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated, multidisciplinary approach for drug safety assessment.
    Li AP
    Drug Discov Today; 2004 Aug; 9(16):687-93. PubMed ID: 15341779
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety issues in scale-up of chemical processes.
    Stoessel F
    Curr Opin Drug Discov Devel; 2001 Nov; 4(6):834-9. PubMed ID: 11899622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmaceutical market research of non-steroidal anti-inflammatory medical cures in the city of Kutaisi].
    Khmelidze M; Eriashvili V; Abuladze N; Dugashvili N
    Georgian Med News; 2006 Dec; (141):87-91. PubMed ID: 17261896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A deep-drawn sigh from a clinician].
    Hill S
    Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1703-4. PubMed ID: 15976848
    [No Abstract]   [Full Text] [Related]  

  • 12. Coxibs and cardiovascular risk.
    Allen MJ; McLean-Veysey P; Fleming I
    CMAJ; 2005 Oct; 173(8):853. PubMed ID: 16217098
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.
    Coplan PM; Noel RA; Levitan BS; Ferguson J; Mussen F
    Clin Pharmacol Ther; 2011 Feb; 89(2):312-5. PubMed ID: 21160469
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugs, science, the press, and politics: an unwieldy mélange toward the public good.
    Assael LA
    J Oral Maxillofac Surg; 2005 Mar; 63(3):289-90. PubMed ID: 15742275
    [No Abstract]   [Full Text] [Related]  

  • 15. [Five turbulent years of coxibers. Where did the principle of caution go?].
    Håkansson J; Rosenberg P
    Lakartidningen; 2005 May 2-15; 102(18-19):1432-4. PubMed ID: 15929426
    [No Abstract]   [Full Text] [Related]  

  • 16. Keeping up with drug allergy.
    Coleman JW
    Clin Exp Allergy; 1996 Dec; 26(12):1341-2. PubMed ID: 9027432
    [No Abstract]   [Full Text] [Related]  

  • 17. A systematic approach to preclinical and clinical safety biomarker qualification incorporating Bradford Hill's principles of causality association.
    Chetty RK; Ozer JS; Lanevschi A; Schuppe-Koistinen I; McHale D; Pears JS; Vonderscher J; Sistare FD; Dieterle F
    Clin Pharmacol Ther; 2010 Aug; 88(2):260-2. PubMed ID: 20592723
    [No Abstract]   [Full Text] [Related]  

  • 18. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
    Weber AA; Hohlfeld T; Harder S
    Thromb Haemost; 2006 Oct; 96(4):413-6. PubMed ID: 17003916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk assessment, drug approval, and liability.
    Somberg JC
    Am J Ther; 2006; 13(3):181-2. PubMed ID: 16772756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.